Fibromyalgia, Migraines & The Science Of Clinical A theoretical syndrome, clinical endocannabinoid deficiency, could provide new insight. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, The theory of clinical endocannabinoid deficiency (CED) was .. in-depth historical and scientific review of cannabis in migraine treatment. Migraine, Fibromyalgia, Irritable Bowel Syndrome and other. Treatment-Resistant underlying clinical endocannabinoid deficiency that may be suitably treated available science at the twilight of the 19th century was.
Clinical Fibromyalgia, Deficiency Of The Migraines & Science Endocannabinoid
According to the CECD hypothesis, treatment of migraine using exogenous cannabinoids could be achieved with low doses due to predisposition for elevated neuronal excitability. The CECD-causing deficiencies can appear for congenital reasons, or can be acquired.
There is a long history of using cannabinoids for effective treatment of pain conditions. Due to their long-standing status of out-lawed substances Baron, , it is worth taking a look at the arguments still standing in the way of legalization. Overall, targeting ECS with peripherally acting drugs is a promising strategy for development of safe migraine treatments. However, there are still many insufficiently explored issues that may be detrimental for this seemingly harmless treatment.
Regularly experiencing chronic migraine pain can have adverse impacts on social relationships and job status which can lead into psychological distress Ramsden et al. In a study of the cannabis use for self-medication in Germany, Austria and Switzerland, Another group found that the self-treatment outcome was highly variable, with low doses tending to alleviate migraine while higher doses even triggering headaches Lu and Anderson, These findings call for creating a highly specific prescription for individual patients, which would be required for safe and successful treatment plan.
One of the main problems arising from the long-term usage of cannabis is the physical reliance on the pCBs, mainly THC. Moreover, there is evidence that patients can develop tolerance for pCBs Kandasamy et al. A crucial point when considering cannabinoid treatment is that smoking marijuana is the most common method of pCB self-administration. When self-administering pCBs via smoking, the relief seekers often use marijuana mixed with tobacco leaves.
In view of the recently established crosstalk between nicotinic cholinergic and ECS Scherma et al. Particularly interesting is the ability of the endogenous nicotinic antagonist kynurenic acid to counteract the addictive effects of CBs Justinova et al.
Notably, new derivatives of kynurenic acid were suggested recently as promising medicines for migraine Greco et al. Interestingly, the main migraine mediator CGRP can reduce the activity of nicotinic receptors Giniatullin et al. Cannabidiol CBD , the second most prevalent pCB, should also be explored in relation to migraine treatment.
This stands as an important milestone paving the way for possible repurposing of this CBD-based drug for treating migraine, as well as other related neurological conditions. In summary, cannabinoids — due to their anticonvulsive, analgesic, antiemetic, and anti-inflammatory effects — present a promising class of compounds for both acute and prophylactic treatment of migraine pain. In view of the rapidly unfolding changes in the legal status of cannabis, research on endo cannabinoids has become pertinent once again.
Formal approval of a cannabinoid-based drug for other pathologies opens a possibility for repurposing these agents also to treat migraine. The abundance of CB1 receptors in the brain makes them an attractive target for treatment of migraine via blocking not only peripheral but also the central nociceptive traffic and reducing the pathologically enhanced cortical excitability predisposing to CSD. CB2 receptors in immune cells can be targeted to reduce the inflammatory component associated with severe forms of migraine.
Exogenous compounds lacking the unwanted peripheral pro-nociceptive component or eCBs generated via inhibited degradation pathways and combined with other supportive agents are most desirable for this aim. Moreover, primary stratification of patients to identify and predict the effectiveness of cannabinoid treatment can greatly improve the efficiency of this approach.
RG was supported by the Finnish Academy grant and by the program of competitive growth of Kazan Federal University and the subsidy 6. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Targeting the endocannabinoid system: Cannabinoid CB1 receptor activation inhibits trigeminovascular neurons.
Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: Molecular targets of cannabidiol in neurological disorders. On the g-protein-coupled receptor heteromers and their allosteric receptor-receptor interactions in the central nervous system: Cannabinoid receptors CB1 and CB2 form functional heteromers in brain.
Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Endocannabinoid signaling in autism. Endovanilloids are potential activators of the trigeminovascular nocisensor complex. Differential neuromodulatory role of endocannabinoids in the rodent trigeminal sensory ganglion and cerebral cortex relevant to pain processing.
Prostaglandins Other Lipid Mediat. Heteroreceptor complexes and their allosteric receptor—receptor interactions as a novel biological principle for integration of communication in the CNS: Turning over a new leaf: Active endocannabinoids are secreted on extracellular membrane vesicles. Plasma levels of the endocannabinoid anandamide, related N-acylethanolamines and linoleic acid-derived oxylipins in patients with migraine.
Fatty Acids , 15— Direct activation of capsaicin receptors by products of lipoxygenases: The international classification of headache disorders, 3rd edition beta version. A systematic review of the antipsychotic properties of cannabidiol in humans.
Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. Release of CGRP from mouse brainstem slices indicates central inhibitory effect of triptans and kynurenate. Spreading depression triggers headache by activating neuronal Panx1 channels. Effect of cannabinoid receptor activation on spreading depression. PubMed Abstract Google Scholar. Serotonergic mechanisms of trigeminal meningeal nociception: Migraine pain and nociceptor activation—where do we stand?
Cannabinoid signaling in health and disease. Intracellular trafficking of anandamide: The role of the endocannabinoid system in eating disorders: CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Cannabinoids as novel anti-inflammatory drugs. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia.
Exposure to marijuana smoke impairs memory retrieval in mice. Targeting cannabinoid signaling in the immune system: Regulation of nausea and vomiting by cannabinoids. Trigger factors and premonitory features of migraine attacks: Handbook of Cannabis and Related Pathologies: Spreading depression requires microglia and is decreased by their M2a polarization from environmental enrichment.
Targeted alterations in dietary n-3 and n-6 fatty acids improve life functioning and reduce psychological distress among chronic headache patients: Calcitonin gene-related peptide CGRP: Clinical endocannabinoid deficiency reconsidered: Adenosine down-regulates giant depolarizing potentials in the developing rat hippocampus by exerting a negative control on glutamatergic inputs.
Interactions between the endocannabinoid and nicotinic cholinergic systems: Exploring the role of microglia in cortical spreading depression in neurological disease.
Endocannabinoids limit excessive mast cell maturation and activation in human skin. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Fatty Acids 66, — Nonpsychotropic cannabinoid receptors regulate microglial cell migration.
Hunting for origins of migraine pain: Synthesis and biological evaluation of bivalent ligands for the CB1 receptor.
The light and sound sensitivity that results from migraines may be due to an overactive nervous system. The ECS is renowned for regulating such imbalances Russo, Some have suggested that the root cause of migraines can be traced back to the trigeminovascular system, which brings blood to the brain. Studies have shown that endocannabinoids can influence this system. Migraines and cluster headaches may be best managed with a treatment that is an agonist of the CB1 receptor.
In the case of migraines, one study found that while a CBD and THC treatment was not necessarily more effective than existing anti-migraine treatments, the side effects were significantly reduced.
Fascinatingly, cannabis was a common treatment for migraines in Europe and North America from the mids until the s, a time when the herb was being prohibited around the globe. As governments all over the world look into the benefits of medical cannabis, the number of high-quality studies being carried out in clinical settings is sure to increase.
With time, we should get an in-depth look at the potential of cannabinoids as a treatment for fibromyalgia, migraines and other illnesses. As our understanding of the ECS deepens, we may learn more about the wide-scale implications of dysfunction in the system. A gloved scientist with a vial of CBD and a hemp leaf.
Furthermore, more research needs to be done on the possible interactions cannabinoids have with receptors outside of the ECS and the effects this may have on the body.
However, the theory has certainly fleshed out since There are studies that suggest medical cannabis and CBD can have a therapeutic effect for certain conditions. He reported that excessive levels of endocannabinoids could also be damaging for health, potentially leading to obesity and hepatic fibrosis.
There are dozens of cannabinoids in hemp and cannabis. Research indicates that whole-plant tinctures can be preferable to isolates of just one chemical. Given that endocannabinoid imbalances differ from patient to patient, the ideal medication for these imbalances may vary too. The market is getting saturated with many different CBD brands. Elliot Cornish is a British cannabis advocate, who writes mostly about the benefits of CBD and the prospects for legalization around the world.
Fibromyalgia attacked my mother body more than 3 years ago after her knee surgery. She has been in a wheelchair for about six months, and she used a cane for another six months. Your email address will not be published. September 27, November 26, at Leave a Reply Cancel reply Your email address will not be published.
This study examines the concept of clinical endocannabinoid deficiency (CECD), Migraine, fibromyalgia, IBS and related conditions display common clinical, supported by the National Academies of Science, Engineering and Medicine. linked to Clinical Endocannabinoid Deficiency (CED) are migraines, fibromyalgia,  What is the science to support these observations?. ISSUE BRIEF ON CLINICAL ENDOCANNABINOID DEFICIENCY Cannabis Review Panel, and to interested members of the public scientific studies of cannabis evidence of CED: migraine, fibromyalgia, and irritable bowel syndrome.